CS1 (SLAMF7, CRACC) is a rational target for myeloma CAR-T therapy since expression of CS1 is uniformly high on myeloma cells independent of cytogenetic abnormalities, genomic mutations, or disease stage [8, 9]. This evidence concerns the gene SLAMF7 and plasma cell myeloma.